Lannett (LCI), FDA Reach Agreement Over SPA for C-Topical Phase III
Tweet
Share
E-mailGet Alerts LCI Hot Sheet
Join SI Premium – FREE
Lannett Company, Inc. (AMEX: LCI) has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA), regarding the design of a Phase III study of the company’s Cocaine HCl topical solution product, C-Topical.
The Phase III trial will be a randomized, prospective, multi-site, double-blind, placebo-controlled, parallel-group study of C-Topical™ Solution as an anesthetic prior to a diagnostic procedure or surgery. The primary endpoint for the trial is analgesic success immediately after application and sustained throughout the diagnostic procedure or surgery. The study will enroll at least 500 subjects.
The Phase III trial will be a randomized, prospective, multi-site, double-blind, placebo-controlled, parallel-group study of C-Topical™ Solution as an anesthetic prior to a diagnostic procedure or surgery. The primary endpoint for the trial is analgesic success immediately after application and sustained throughout the diagnostic procedure or surgery. The study will enroll at least 500 subjects.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Cytek faces $56M damages award in Beckman Coulter patent case
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
